Sunovion Pharmaceuticals Inc. said the U.S. Food and Drug Administration has accepted its applications to expand the indication of its schizophrenia drug, Latuda to be used as a treatment for bipolar disorder. One application requests approval for Latuda to be used in combination with other drugs, and the other requests an approval to be prescribed as a bipolar treatment on its own.